Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

New concepts in understanding antiarrhythmic effects

New concepts in understanding antiarrhythmic effects Radiofrequency catheter ablation (RFCA) has been established as a curative alternative to antiarrhythmic drug (AAD) therapy in patients with supraventricular arrhythmias other than atrial fibrillation (AF). Many currently used AAD have limited efficacy and cause cardiac and extracardiac adverse effects. There is a need for new AADs with high efficacy and a favorable safety profile in AF patients. Dronedarone and vernakalant are promising new agents with a low risk profile up to date. Effectively restoring sinus rhythm is a crucial aspect in heart failure (HF) patients with AF. RFCA, including pulmonary vein isolation and other left and right atrial ablation targets, offers the possibility of long-term suppressive or curative therapy of AF. New antiarrhythmic drug and interventional concepts in AF and HF patients are discussed. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Research in Cardiology Supplements Springer Journals

New concepts in understanding antiarrhythmic effects

Loading next page...
 
/lp/springer-journals/new-concepts-in-understanding-antiarrhythmic-effects-DKRJSrqYs0

References (29)

Publisher
Springer Journals
Copyright
Copyright © 2010 by Springer-Verlag
Subject
Medicine & Public Health; Cardiac Surgery; Angiology; Internal Medicine; Diagnostic Radiology; Cardiology
ISSN
1861-0706
eISSN
1861-0714
DOI
10.1007/s11789-010-0010-2
Publisher site
See Article on Publisher Site

Abstract

Radiofrequency catheter ablation (RFCA) has been established as a curative alternative to antiarrhythmic drug (AAD) therapy in patients with supraventricular arrhythmias other than atrial fibrillation (AF). Many currently used AAD have limited efficacy and cause cardiac and extracardiac adverse effects. There is a need for new AADs with high efficacy and a favorable safety profile in AF patients. Dronedarone and vernakalant are promising new agents with a low risk profile up to date. Effectively restoring sinus rhythm is a crucial aspect in heart failure (HF) patients with AF. RFCA, including pulmonary vein isolation and other left and right atrial ablation targets, offers the possibility of long-term suppressive or curative therapy of AF. New antiarrhythmic drug and interventional concepts in AF and HF patients are discussed.

Journal

Clinical Research in Cardiology SupplementsSpringer Journals

Published: Mar 16, 2010

There are no references for this article.